Martin Shkreli violated lifetime pharma industry ban, FTC and states say in contempt claim
Shkreli was banned from the pharmaceutical industry after a trial found that he organized an illegal scheme to perpetuate a monopoly for the drug Daraprim.
Shkreli was banned from the pharmaceutical industry after a trial found that he organized an illegal scheme to perpetuate a monopoly for the drug Daraprim. This story matters for Finance & Markets readers tracking finance. Reported by cnbc.com. Read the full original at the source link below.
Originally reported by cnbc.com. InvestorsWire.com curates and briefs the finance & markets stories that matter. Our editorial policy →
Get the daily finance & markets signal